Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer's disease

Alzheimer's Research & Therapy
Philip S J WestonNick C Fox

Abstract

To investigate how serum neurofilament light (NfL) concentration changes through the course of disease in familial Alzheimer's disease (FAD) and to assess when NfL concentration first increases. NfL was measured using an ultrasensitive immunoassay in 117 serum samples from 61 individuals from families with PSEN1 or APP mutations in a longitudinal study (mean ± SD = 1.9 ± 1.1 visits/patient; inter-visit interval = 1.8 ± 1.1 years). The relationship between NfL concentration and estimated years to/from symptom onset (EYO) was modelled using linear regression, including all time points and robust standard errors to allow for repeated measurements, adjusting for age at visit and sex. Also, for the 27 participants who became symptomatic (during or before the study), NfL concentration was also modelled against known actual years to/from onset (AYO). There were 15 non-carriers and 46 mutation carriers (21 symptomatic; 25 presymptomatic). NfL concentration was increased (p = 0.045) in mutation carriers compared with non-carriers 15 years prior to expected symptom onset, increasing progressively thereafter. There was a significant inter- and intra-individual variability in the longitudinal pattern of change. Modelling NfL for the 27 mut...Continue Reading

References

Sep 22, 2006·Lancet Neurology·Basil H RidhaNick C Fox
Jul 13, 2012·The New England Journal of Medicine·Randall J BatemanUNKNOWN Dominantly Inherited Alzheimer Network
Feb 6, 2013·Journal of Alzheimer's Disease : JAD·Rachael I ScahillNick C Fox
Mar 13, 2013·Lancet Neurology·Victor L VillemagneUNKNOWN Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group
Nov 7, 2013·Proceedings of the National Academy of Sciences of the United States of America·Tammie L S BenzingerJohn C Morris
Jun 15, 2014·Neurology·Davis C RymanUNKNOWN Dominantly Inherited Alzheimer Network
Mar 28, 2017·JAMA Neurology·Niklas MattssonUNKNOWN Alzheimer’s Disease Neuroimaging Initiative

❮ Previous
Next ❯

Citations

Aug 23, 2019·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Michael BenatarAndrea Malaspina
Apr 7, 2020·Molecular Psychiatry·Henrik Zetterberg, Barbara B Bendlin
May 15, 2020·Brain : a Journal of Neurology·Arie R GafsonPaul M Matthews
Sep 20, 2020·Annals of Clinical and Translational Neurology·Yu GuoUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Mar 27, 2020·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Kunal DhimanRalph N Martins
Jul 28, 2020·Journal of Personalized Medicine·Syed Haris Omar, John Preddy
Jan 4, 2020·Therapeutic Advances in Neurological Disorders·Marta Milà-AlomàJosé Luís Molinuevo
Jul 18, 2020·Journal of Neurochemistry·Pratishtha ChatterjeeRalph N Martins
Nov 5, 2020·Annals of Clinical and Translational Neurology·Christian BarroHoward L Weiner
Dec 18, 2020·Science Translational Medicine·Filipe B RodriguesEdward J Wild
Feb 21, 2021·Molecular Neurodegeneration·Henrik Zetterberg, Kaj Blennow
Jun 12, 2020·Neurobiology of Disease·Stephanie A SchultzUNKNOWN Dominantly Inherited Alzheimer Network
Jun 17, 2020·British Journal of Anaesthesia·Stacie DeinerRoderic Eckenhoff
Jun 11, 2021·Frontiers in Neuroscience·Lorenzo GaetaniMassimiliano Di Filippo
Jul 9, 2021·Journal of Neuroscience Methods·Christian Barro, Henrik Zetterberg

❮ Previous
Next ❯

Software Mentioned

Stata

Related Concepts

Related Feeds

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.